Welcome to our dedicated page for TRIL news (Ticker: TRIL), a resource for investors and traders seeking the latest updates and insights on TRIL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TRIL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TRIL's position in the market.
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) announced that the Supreme Court of British Columbia approved its plan of arrangement with PF Argentum ULC, a subsidiary of Pfizer Inc. Under this arrangement, Trillium shareholders, excluding Pfizer and its affiliates, will receive US$18.50 per share in cash. Warrant holders have the option for cash payments based on the warrant's exercise price or its Black Scholes value. The transaction is pending regulatory approvals and is expected to complete in late 2021 or early 2022, resulting in Trillium's shares delisting from the Toronto Stock Exchange and NASDAQ.
Frazier Healthcare Partners announced the closing of Frazier Life Sciences Public Fund, raising nearly
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) announced that its securityholders approved a statutory arrangement with PF Argentum ULC, a subsidiary of Pfizer Inc. The arrangement allows PF Argentum to acquire all outstanding shares and warrants of Trillium not owned by Pfizer. This resolution received overwhelming support, with 99.61% of votes cast in favor. Shareholders will receive US$18.50 per share in cash, while warrant holders can opt for cash or Black Scholes value. The transaction is subject to court and regulatory approvals, expected to close in late 2021 or early 2022.
Pfizer has announced a definitive agreement to acquire Trillium Therapeutics for an implied equity value of $2.26 billion, translating to $18.50 per share, a 118% premium over its 60-day average price. This acquisition aims to enhance Pfizer’s oncology portfolio, specifically in hematological malignancies, with Trillium’s TTI-622 and TTI-621 immuno-therapeutics. These lead molecules target the SIRPα–CD47 axis and are in Phase 1b/2 development. The acquisition is contingent on shareholder and regulatory approvals.
Pfizer (NYSE: PFE) has announced its definitive agreement to acquire Trillium Therapeutics (NASDAQ/TSX: TRIL) for an equity value of $2.26 billion, equating to $18.50 per share, marking a significant 118% premium. The acquisition aims to enhance Pfizer's oncology portfolio, especially in treating blood cancers, by integrating Trillium's lead molecules, TTI-622 and TTI-621, which target the SIRPα-CD47 axis. These molecules are in advanced clinical trials and show promise as therapies for various hematological malignancies.
Trillium Therapeutics (NASDAQ/TSX: TRIL) reported key financial results and operational updates for Q2 2021. The company had cash and cash equivalents of $264.5 million as of June 30, 2021, down from $291.2 million at year-end 2020. R&D expenses rose to $19.9 million, compared to $12.2 million in the prior year, driven by increased clinical trial costs. Net loss decreased to $29.3 million from $39.5 million year-over-year. Trillium has initiated four out of six planned studies, targeting multiple myeloma and other cancers.
Trillium Therapeutics (NASDAQ/TSX: TRIL) has initiated dosing of its first TP53-mutated acute myeloid leukemia (AML) patient with TTI-622, an investigational checkpoint inhibitor. This treatment is combined with azacitidine and aims to improve patient outcomes in a group with limited therapeutic options. The Phase 1b/2 study will enroll 25 patients to assess safety and response rates. Trillium continues to expand its clinical programs targeting CD47, enhancing its solid foundation with a robust cash position, and is expected to release significant data over the coming years.
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) has initiated dosing of its first acute myeloid leukemia (AML) patient with TTI-622, an investigational checkpoint inhibitor, in combination with azacitidine and venetoclax. This marks the second cohort in a Phase 1b/2 program aimed at evaluating TTI-622 across various cancers. The trial focuses on elderly patients or those unfit for intensive chemotherapy, with the primary endpoints being safety and complete response rate. The combination aims to address significant unmet medical needs in AML treatment.
Trillium Therapeutics (NASDAQ/TSX: TRIL) announced the appointment of Catherine Mackey, Ph.D., to its Board of Directors, effective immediately. With over 30 years in the pharmaceutical sector, Dr. Mackey previously held senior roles at Pfizer and is well-regarded in R&D. Her expertise is expected to support Trillium as it advances its lead product candidates into Phase 1b/2 trials targeting hematologic malignancies and solid tumors. The company aims to produce substantial new clinical data in the upcoming years, reinforcing its position in the competitive immuno-oncology landscape.
Trillium Therapeutics (NASDAQ/TSX: TRIL) announced the dosing of the first patient in a Phase 1b/2 study of TTI-621, an investigational checkpoint inhibitor, combined with doxorubicin for treating leiomyosarcoma (LMS). This trial aims to enroll approximately 60 newly diagnosed LMS patients, focusing on safety and overall response rate. TTI-621 is designed to enhance phagocytosis and improve tumor cell destruction by blocking the CD47-SIRPα interaction. This marks Trillium's first solid tumor clinical trial, emphasizing the unmet need in treating metastasized LMS.
